文献速递泌尿生殖与妇科肿瘤放疗放疗物理与技术

超声引导下大分割放射治疗前列腺癌(RAPHYDUS):巴西公共卫生系统研究

Radiation Therapy for Prostate Cancer Using HYpofractionation Directed by UltraSound (RAPHYDUS): A Brazilian Public Health Care System Study.
PubMed 文献 · Pract Radiat Oncol · 2022-04-22

这项单中心前瞻性观察研究纳入2016至2020年132例前列腺癌患者,评估影像引导下短程剂量递增大分割放疗联合或不联合雄激素抑制治疗的毒性。111例完成放疗的患者中,急性泌尿生殖系统和胃肠道毒性分别有4例(4%)和7例(8%)达到最高级别。作者认为66 Gy分22次方案可行,急性胃肠道和泌尿生殖系统毒性低,需进一步随访报告晚期毒性和结局。

要点

  • 111例完成放疗患者中,急性泌尿生殖系统毒性达3级者4例(4%),急性胃肠道毒性达2级者7例(8%)。
  • 国际前列腺症状评分平均值从治疗前4.8升至第4周14.0,治疗结束后3个月恢复至5.7。
  • 作者认为66 Gy分22次大分割放疗方案可行,急性胃肠道和泌尿生殖系统毒性低。

核心结论

  • 当前大分割放疗剂量递增试验已证明给予66 Gy分22次照射可行,急性胃肠道和泌尿生殖系统毒性低。
  • 需进一步随访以报告晚期毒性和结局。

研究设计与样本

  • 单中心前瞻性观察研究,纳入2016年至2020年132例前列腺癌患者。
  • 患者接受影像引导放疗(84%),采用三维适形放疗(91%)或调强放疗(9%)。
  • 处方总剂量为66 Gy(63%)、63 Gy(12%)和60 Gy(24%),分别分22、21或20次每日照射,取决于危及器官剂量约束。
  • 急性毒性采用放射治疗肿瘤学组标准和国际前列腺症状指数评分,生活质量数据采用扩展前列腺癌指数综合问卷收集(评分范围0-100)。
  • 研究人群为3年期间完成放疗的111例患者。

主要发现

  • 风险分组为低危(12%)、中危(32%)和高危(56%)。
  • 无患者有可疑淋巴结。
  • 90%接受雄激素抑制治疗。
  • 111例可评估患者中,急性泌尿生殖系统毒性最高达3级者4例(4%),急性胃肠道毒性最高达2级者7例(8%)。
  • 国际前列腺症状评分平均值从治疗前4.8升至第4周14.0,治疗结束后3个月恢复至5.7。

局限性

  • 需进一步随访以报告晚期毒性和结局。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: This study evaluated the toxicity associated with a short course dose-escalated hypofractionated radiation therapy (HFRT) using image guided RT with or without androgen suppression therapy in patients with prostate cancer. METHODS AND MATERIALS: This single-center prospective observational study included 132 patients with prostate cancer from 2016 to 2020. Patients received HFRT using image guided RT (84%) with 3-dimensional (91%) or intensity modulated RT (9%). Total prescribed doses were 66 Gy (63%), 63 Gy (12%), and 60 Gy (24%) in 22, 21, or 20 daily fractions depending on organ-at-risk dose constraints. Acute toxicity was scored using Radiation Therapy Oncology Group criteria and the international prostate symptom index. The expanded prostate cancer index composite questionnaire was used to collect quality of life data (ranging from 0-100). RESULTS: The study population consisted of 111 patients who completed RT during a period of 3 years. The risk groups were as follows: low risk (12%), intermediate (32%), and high (56%). None of the patients had suspicious lymph nodes. Ninety percent received androgen suppression therapy. Maximum acute genitourinary and gastrointestinal toxicity peaked at grade 3 in 4 of 111 evaluated patients (4%) and at grade 2 in 7 of 111 evaluated patients (8%), respectively. The average international prostate symptom score increased from 4.8 at pretreatment to 14.0 during week 4 and normalized (5.7) 3 months after treatment completion. CONCLUSIONS: The current HFRT dose-escalation trial has demonstrated the feasibility of administering 66 Gy in 22 fractions with low acute gastrointestinal and genitourinary toxicities. Further follow-up will report late toxicities and outcomes.

来源:Pract Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Faustino FLC, Altei WF, Canton HP, et al. Radiation Therapy for Prostate Cancer Using HYpofractionation Directed by UltraSound (RAPHYDUS): A Brazilian Public Health Care System Study. Pract Radiat Oncol. 2022. PMID: 35462055. doi:10.1016/j.prro.2022.04.001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。